Ebola and Marburg Infections Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022-2027

Report Code: HCR 0956 Report Format: PDF + Excel

Ebola and Marburg Infections Market Overview

Ebola and Marburg Infections Market size is estimated to reach $134.4 million by 2027, growing at a CAGR of 13.4% during the forecast period 2022-2027. Ebola virus disease (EVD), previously recognized as Ebola hemorrhagic fever, is a rare but serious, frequently deadly ailment in humans. The Ebola virus brings about an acute, severe ailment that is frequently deadly if untreated. EVD earliest appeared in 1976 in 2 concurrent outbreaks, one in what is presently Nzara, South Sudan and the other in Yambuku, DRC. The latter happened in a village near the Ebola River, from which the ailment derives its name. Marburg virus disease (MVD), previously recognized as Marburg hemorrhagic fever, is a serious, frequently deadly ailment in humans. Marburg virus is the causative agent of Marburg virus disease (MVD), an ailment with a case fatality ratio of up to 88%, however, can be much lesser with good patient care. Marburg virus disease was first discovered in 1967 subsequent to concurrent outbreaks in Marburg and Frankfurt in Germany; and in Belgrade, Serbia. Ebolaviruses and Marburgviruses (family Filoviridae) are among the most virulent pathogens for humans and very large apes bringing about serious hemorrhagic fever and demise within a matter of days. Marburg and Ebola viruses are filamentous filoviruses that are different from each other, however, they bring about clinically comparable ailments characterized by hemorrhagic fevers and capillary leakage. Rousettus aegyptiacus, fruit bats of the Pteropodidae family, are thought to be natural hosts of the Marburg virus. Symptoms of Marburg and Ebola virus infection are very comparable. During the 2nd week of symptoms, either defervescence happens and patients commence recovery or patients develop fatal multiple organ failure. Recovery is extended and may be difficult by the occurrence of recurrent hepatitis, transverse myelitis and orchitis. The case fatality rate ranges from 25 to 90%. Certain typical Ebola and Marburg Infections Industry applications include coming up with superior ways to diagnose and treat Ebola virus disease and Marburg fevers and utilizing applied research to develop and test vaccines and treatments.

The soaring awareness regarding hemorrhagic fever caused by filoviruses like the Ebola virus and Marburg virus and the government-initiated program in Africa is set to drive the Ebola and Marburg Infections Market. The great research development financing in diagnostic and treatment investigations and the government and non-governmental organization (NGO) backing for market players to research efficient treatment are set to propel the growth of the Ebola and Marburg Infections Industry during the forecast period 2022-2027. This represents the Ebola and Marburg Infections Industry Outlook.

Ebola and Marburg Infections Market Report Coverage

The Ebola and Marburg Infections Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Ebola and Marburg Infections Market.

By Type Of Disease: Ebola Virus Disease (EVD) Or Ebola Hemorrhagic Fever, Marburg Virus Disease (MVD) Or Marburg Hemorrhagic Fever.
By Diagnostic Technique: Antibody-Capture Enzyme-Linked Immunosorbent Assay (ELISA), Antigen-Capture Detection Tests, Serum Neutralization Test, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Assay, Electron Microscopy, Virus Isolation By Cell Culture.
By Treatment: Supportive Care, Antiviral Therapy.
By End Use Industry: Hospitals And Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Research Institutes, Others.
By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America) and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, the Rest Of The World (Ebola and Marburg Infections market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of Ebola Virus Disease (EVD) or Ebola Hemorrhagic Fever and Marburg Virus Disease (MVD) or Marburg Hemorrhagic Fever, caused by filoviruses termed Ebola virus and Marburg virus in African countries like Guinea, the Democratic Republic of the Congo, Uganda, Angola, Kenya and South Africa, as per updates by World Health Organization (WHO), in the Rest Of The World region.
  • Ebola and Marburg Infections Market growth is being driven by the increasing Ebola outbreaks in Guinea which then spread to Sierra Leone and Liberia and cases of Marburg Virus Disease (MVD) in Uganda and Angola. The Democratic Republic of the Congo, Kenya and South Africa. However, as per World Health Organization (WHO), presently, there are no vaccines or antiviral treatments certified for Marburg Virus Disease (MVD) or Marburg Hemorrhagic Fever, which is one of the major factors hampering the growth of Ebola and Marburg Infections Market. 
  • Ebola and Marburg Infections Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Ebola and Marburg Infections Market report.

Ebola and Marburg Infections Market: Market Share (%) by Region, 2021
Ebola and Marburg Infections Market
For More Details on This Report - Request for Sample

Ebola and Marburg Infections Market Segment Analysis - by Type Of Disease

The Ebola and Marburg Infections Market based on the type of disease can be further segmented into Ebola Virus Disease (EVD) Or Ebola Hemorrhagic Fever, Marburg Virus Disease (MVD) or Marburg Hemorrhagic Fever. The Ebola Virus Disease (EVD) Segment held the largest Ebola and Marburg Infections market share in 2021. This growth is owing to the increasing outbreaks of Ebola Hemorrhagic fever in Africa and the greater contagiousness of the Ebola virus than the Marburg virus. The Ebola virus is a filovirus. The surging count of vaccines developed to curb the spread of Ebola outbreaks in Guinea and the Democratic Republic of the Congo (DRC) is further propelling the growth of the Ebola Virus Disease (EVD) segment.

Furthermore, the Marburg Virus Disease (MVD) segment is estimated to grow with the fastest CAGR of 14.5% during the forecast period 2022-2027 owing to the recent outbreak of Marburg Hemorrhagic Fever in Ghana in Africa.

Ebola and Marburg Infections Market Segment Analysis - by Diagnostic Technique

The Ebola and Marburg Infections Market based on diagnostic techniques can be further segmented into Antibody-Capture Enzyme-Linked Immunosorbent Assay (ELISA), Antigen-Capture Detection Tests, Serum Neutralization Test, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Assay, Electron Microscopy, Virus Isolation By Cell Culture. The Antibody-Capture Enzyme-Linked Immunosorbent Assay (ELISA) Segment held the largest Ebola and Marburg Infections market share in 2021. This growth is owing to the development of immunoglobulin G (IgG) ELISA utilizing His-tagged recombinant protein (His-EBO-NP) and the Carboxy-terminal halves (C-terminal halves) of the nucleoproteins (NPs) of Ebola virus (EBO) and Marburg virus (MBG) as antigens. The outcomes signify that ELISA systems prepared with the recombinant NPs of EBO and MBG are valuable tools for the diagnosis of EBO and MBG infections and for seroepidemiological field investigations. The soaring sensitivity and specificity of the IgG ELISA with the recombinant NPs in discovering EBO and MBG antibodies is further propelling the growth of this segment.

Furthermore, the Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Assay segment is estimated to grow with the fastest CAGR of 15.4% during the forecast period 2022-2027 owing to the surging detection of ebolavirus RNA using end-point RT-PCR (agarose gel visualization of amplification products) and quantitative RT-PCR (Q-RT-PCR), with fluorescent detection using an intercalating dye or detection with the use of 5' hydrolysis probe assays.

Ebola and Marburg Infections Market Segment Analysis - by Geography

The Ebola and Marburg Infections Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. Rest of the World (Ebola and Marburg Infections Market) held the largest Ebola and Marburg Infections market share with 40% of the overall market in 2021. The growth of this region is owing to the increasing outbreaks of Ebola Virus Disease and Marburg Virus Disease in Africa in the Rest of the World region. Ebola Virus Disease and Marburg Virus Disease are caused by filoviruses termed Ebola virus and Marburg virus. Marburg virus brings about serious viral hemorrhagic fever and hepatitis in humans. The increasing transmission from fruit bats and rousettus aegyptiacus together with the human-to-human transmission is further propelling the growth of the Ebola and Marburg Infections Market in the Rest Of The World region.

Furthermore, the Rest Of The World region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the soaring government-initiated programs in Africa. The recognition of the Ethiopian Highlands and areas spread across East Africa as added potentially unidentified transmission areas is further fuelling the progress of the Ebola and Marburg Infections Market in the Rest Of The World region.

Ebola and Marburg Infections Market Drivers

Surging Developments Pertaining to Ebola Virus are Projected to Drive the Growth of Ebola and Marburg Infections Industry:

The Ebola virus is a filovirus that is among the most hazardous viral pathogens, with a case fatality rate of up to 90%. Ebola virus disease (EVD), previously recognized as Ebola hemorrhagic fever, is a rare but serious, frequently fatal ailment in humans caused by the Ebola virus. A reverse genetics system is a significant tool for examining viruses by generating mutant viruses or producing safer and more useful model systems. An Ebola Virus (EBOV) life cycle modeling system has been developed in which subviral particles can instinctively reproduce in cell culture. Additionally, this system can be engaged to save infectious virions of homologous or heterologous EBOV isolates utilizing either sense or antisense viral RNA genomes. To conclude, a novel tool has been developed for EBOV research. The surging developments pertaining to Ebola Virus are therefore fuelling the growth of the Ebola and Marburg Infections Industry, thereby contributing to the Ebola and Marburg Infections Industry Outlook, during the forecast period 2022-2027.

Recent Outbreak of Marburg Virus Disease in Ghana is Expected to Boost the Growth of the Ebola and Marburg Infections Market:

Marburg virus disease (MVD), previously recognized as Marburg hemorrhagic fever, is a serious, frequently fatal ailment in humans. Marburg virus is a filovirus and is the causative agent of Marburg virus disease (MVD), an ailment with a case fatality ratio of up to 88%. However, it can be much lesser with good patient care. Rousettus aegyptiacus bats are thought to be natural hosts for the Marburg virus. As per the Centers for Disease Control and Prevention (CDC), on July 17, 2022, Ghana announced an outbreak of the Marburg virus disease. Confirmed cases have been recorded in the Ashanti region. The World Health Organization (WHO) is engaging with regional health authorities to recognize cases and handle case examinations, enhance surveillance, recognize sources of transmission and inform communities regarding the chances and hazards of Marburg. The recent outbreak of Marburg Virus Disease in Ghana is therefore driving the growth of the Ebola and Marburg Infections Market during the forecast period 2022-2027.

Ebola and Marburg Infections Market Challenges

After Effects of Ebola Virus and Marburg Virus Disease Treatment are Hampering the Growth of the Ebola and Marburg Infections Market:

Ebola, also termed Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and additional primates, brought about by ebolaviruses. Ebolaviruses are a type of filoviruses. Recovery may commence between seven and 14 days after early symptoms. Those who survive frequently have continuous muscular and joint pain, hepatitis, liver inflammation and decreased hearing and may have extended tiredness, regular weakness, reduced appetite and problem returning to pre-illness weight. Issues with vision may develop. Marburg virus disease (MVD), previously recognized as Marburg hemorrhagic fever, is a serious, frequently fatal ailment in humans bringing about viral hemorrhagic fever. Rousettus Aegyptiacus, fruit bats of the Pteropodidae family, are thought to be natural hosts of the Marburg virus. Symptoms of MVD include hemorrhagic exhibitions between 5 and 7 days with fatal cases normally having some kind of bleeding, frequently from numerous areas. It is hard to clinically differentiate MVD from ailments like malaria, typhoid fever and additional viral hemorrhagic fevers. There is no certified antiviral treatment or vaccine for MVD presently. These issues are thus hampering the growth of the Ebola and Marburg Infections Market.

Ebola and Marburg Infections Industry Outlook

Development of Pipeline Medications and R&D activities are key strategies adopted by players in the Ebola and Marburg Infections Market. The top 10 companies in the Ebola and Marburg Infections market are:

  1. SIGA Technologies Inc.
  2. Bavarian Nordic A/S
  3. NanoViricides, Inc.
  4. AlphaVax, Inc.
  5. Crucell N.V.
  6. Functional Genetics, Inc.
  7. Okairos AG
  8. Immunovaccine, Inc.
  9. Inovio Pharmaceuticals, Inc.
  10. Mapp Biopharmaceutical, Inc.

Recent Developments

  • In April 2021, Bavarian Nordic A/S declared that the firm has accepted a novel supply order from Janssen Pharmaceutica NV, the portion of the Janssen Pharmaceutical Companies of Johnson & Johnson, valued at nearly USD 28 million. Under the contract, Bavarian Nordic will produce and convey bulk drug substance of MVA-BN® Filo vaccine, licensed to Janssen as part of its Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN Filo), which was certified by the European Commission in 2020. Manufacturing of the bulk drug substance will begin in May 2021 and delivery is anticipated to take place in the second half of 2021.
  • In February 2021, researchers at the University of Illinois Chicago recognized a second site on the filovirus glycoprotein to which tiny drug molecules can fasten and avert contamination. The researchers pronounce that tiny drug molecules that obstruct both glycoprotein sites may be more efficient and decrease the hazard of side effects. These findings are recorded in the journal PLOS Pathogens.
  • In July 2020, Bavarian Nordic declared European Marketing Authorization for Ebola Vaccine. European Commission allowed Marketing Authorization for MVABEA (MVA-BN FILO) along with ZABDENO (AD26.ZEBOV), which are taken together forms Jannsen’s Ebola Vaccine Regimen. Approval succeeds a positive opinion by CHMP (Committee for Medicinal Products for Human Use) in May 2020. This concludes the Ebola and Marburg Infections Industry Outlook.

Relevant Reports:

Virology Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0423

Viral Hemorrhagic Fever Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0952

Viral Conjunctivitis Pipeline Drugs Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0882

For more Lifesciences and Healthcare Market reports, please click here

1. Ebola and Marburg Infections Market Overview
    1.1 Definitions and Scope
2. Ebola and Marburg Infections Market - Executive Summary
3. Ebola and Marburg Infections Market – Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Ebola and Marburg Infections Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Ebola and Marburg Infections Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Ebola and Marburg Infections Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porter's five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Ebola and Marburg Infections Market – Strategic Analysis
    7.1 Value Chain Analysis 
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Ebola and Marburg Infections Market – by Type Of Disease (Market Size – US$Million/$Billion) 
    8.1 Ebola Virus Disease (EVD) Or Ebola Hemorrhagic Fever
    8.2 Marburg Virus Disease (MVD) Or Marburg Hemorrhagic Fever
9. Ebola and Marburg Infections Market – by Diagnostic Technique (Market Size – US$Million/$Billion) 
    9.1 Antibody-Capture Enzyme - Linked Immunosorbent Assay (ELISA)
    9.2 Antigen-Capture Detection Tests
    9.3 Serum Neutralization Test
    9.4 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Assay
    9.5 Electron Microscopy
    9.6 Virus Isolation By Cell Culture
10. Ebola and Marburg Infections Market – by Treatment (Market Size – US$Million/$Billion) 
    10.1 Supportive Care
    10.2 Antiviral Therapy
11. Ebola and Marburg Infections Market – by End-use Industry (Market Size – US$Million/$Billion) 
    11.1 Hospitals And Clinics
    11.2 Ambulatory Surgical Centers
    11.3 Diagnostic Centers
    11.4 Research Institutes
    11.5 Others
12. Ebola and Marburg Infections Market - by Geography (Market Size -$Million/Billion)
    12.1 North America
        12.1.1 the U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 Germany
        12.2.2 France
        12.2.3 the UK
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 Japan
        12.3.3 South Korea
        12.3.4 India
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest Of The World
        12.5.1 the Middle East
        12.5.2 Africa
13. Ebola and Marburg Infections Market - Market Entropy
    13.1 New product launches
    13.2 M&A's, collaborations, JVs and partnerships
14. Ebola and Marburg Infections Market – Industry Competition Landscape (Premium)
    14.1 Market Share Analysis
        14.1.1 Market Share by Region – Key Companies
        14.1.2 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. Ebola and Marburg Infections Market – Key Company List by Country Premium (Premium)
16. Ebola and Marburg Infections Market - Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
* "Financials would be provided to private companies on best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.